Oct 02, 2023 / 08:00PM GMT
Geulah Livshits - Chardan Capital Markets - Analyst
Dr. Nathan Jorgensen, CFO of Vor Bio. The format for this session is a fireside chat. And we might open to audience Q&A at the end if there's time.
Questions and Answers:
Geulah Livshits - Chardan Capital Markets - AnalystNathan, thank you so much for joining us today. Can you start off by giving us some high-level introductory comments on Vor for those that might be new to the story? And also highlight for us some recent milestones and upcoming catalysts. And then we'll dive into your pipeline and programs in more detail.
Nathan Jorgensen - Vor Biopharma Inc. - CFO
Thank you. And thank you for having us at the Chardan Conference. So Vor was founded to solve one of the big issues for a cancer drug development. And that's there aren't any really good targets.
And so our approach is, we take a bone marrow transplant for some of these cancers, such as AML, where it's a standard of care. And we delete up a protein. And so then, when that transplant
Trustpilot
